Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells

Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI

Pieraccini S, Saladino G, Sironi M, Francescato P, Cattaneo MG, Vicentini LM, Speranza G and Manitto P: A molecular dynamics study of an endostatin-derived peptide with antiangiogenic activity and of its mutants. Chem Phys Lett. 455:311–315. 2008. View Article : Google Scholar

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al: Broad targeting of angiogenesis for cancer prevention and therapy. Semi Cancer Biol. 35(Suppl): S224–S243. 2015. View Article : Google Scholar

Shimizu K and Oku N: Cancer anti-angiogenic therapy. Biol Pharm Bull. 27:599–605. 2004. View Article : Google Scholar : PubMed/NCBI

O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI

Zatterstrom UK, Felbor U, Fukai N and Olsen BR: Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct. 25:97–101. 2000. View Article : Google Scholar : PubMed/NCBI

Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M and Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem. 274:11721–11726. 1999. View Article : Google Scholar : PubMed/NCBI

Rehn M, Veikkkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K and Vuori K: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA. 98:1024–1029. 2001. View Article : Google Scholar : PubMed/NCBI

Kim YM, Hwang S, Kim YM, Pyunn BJ, Kim TY, Lee ST, Gho YS and Kwon YG: Endostatin blocks vascular endthelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 277:27872–27879. 2002. View Article : Google Scholar : PubMed/NCBI

Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R and Sukhatme VP: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 277:16464–16469. 2002. View Article : Google Scholar : PubMed/NCBI

Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST and Kwon YG: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60:5410–5413. 2000.PubMed/NCBI

Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, Kwon YG and Lee ST: Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519:147–152. 2002. View Article : Google Scholar : PubMed/NCBI

Foda HD and Zucker S: Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 6:478–482. 2001. View Article : Google Scholar : PubMed/NCBI

Hellström-Lindahl E, Ravid R and Nordberg A: Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with A beta levels. Neurobiol Aging. 29:210–221. 2008. View Article : Google Scholar

Bunn PA Jr, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ and Miller YE: Effects of recombinant neutral endopeptidase (EC 3.4.24.11.) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 4:2849–2858. 1998.PubMed/NCBI

Usmani BA, Harden B, Maitland NJ and Turner AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond). 103(Suppl 48): 314S–317S. 2002. View Article : Google Scholar

Renneberg H, Albrecht M, Kurek R, Krause E, Lottspeich F, Aumüller G and Wilhelm B: Identification and characterization of neutral endopeptidase (EC 3.4.24.11) from human prostasomes-localization in prostatic tissue and cell lines. Prostate. 46:173–183. 2001. View Article : Google Scholar : PubMed/NCBI

Albrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T and Aumüller G: Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-Ibeta with IL-1beta acting as a modulator of cellular differentiation. Prostate. 58:82–94. 2004. View Article : Google Scholar

Burns DM, Walker B, Gray J and Nelson J: Breast cancer cell associated endopeptidase EC 24.11 modulates proliferative response to bombesin. Br J Cancer. 79:214–220. 1999. View Article : Google Scholar : PubMed/NCBI

Seals DF and Courtneidge SA: The ADAMs family of metalloproteinases: Multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI

Van der Vorst EP, Keijbeck AA, de Winther MP and Donners MM: A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis. 224:302–308. 2012. View Article : Google Scholar : PubMed/NCBI

Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci. 98:621–628. 2007. View Article : Google Scholar : PubMed/NCBI

Erin N, Zhao W, Bylander J, Chase G and Clawson G: Capsaicin induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat. 99:351–364. 2006. View Article : Google Scholar : PubMed/NCBI

Sumner SC, Gallagher KS, Davis DG, Covell DG, Jernigan RL and Ferretti JA: Conformational analysis of the tachykinins in solution: Substance P and physalaemin. J Biomol Struct Dyn. 8:687–707. 1990. View Article : Google Scholar : PubMed/NCBI

Kurtz MM, Wang R, Clements MK, Cascieria MA, Austin CP, Cunningham BR, Chicchia GG and Liu Q: Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene. 296:205–212. 2002. View Article : Google Scholar : PubMed/NCBI

Koon HW and Pothoulakis C: Immunomodulatory properties of substance P: The gastrointestinal system as a model. Ann NY Acad Sci. 1088:23–40. 2006. View Article : Google Scholar : PubMed/NCBI

Schäffer M, Beiter T, Becker HD and Hunt TK: Neuropeptides: Mediators of inflammation and tissue repair? Arch Surg. 133:1107–1116. 1998. View Article : Google Scholar : PubMed/NCBI

Muangman P, Tamura RN, Muffley LA, Isik FF, Scott JR, Xie C, Kegel G, Sullivan SR, Liang Z and Gibran NS: Substance P enhances wound closure in nitric oxide synthase knockout mice. J Surg Res. 153:201–209. 2009. View Article : Google Scholar :

Chappa AK, Audus KL and Lunte SM: Characteristics of substance P transport across the blood-brain barrier. Pharm Res. 23:1201–1208. 2006. View Article : Google Scholar : PubMed/NCBI

Esteban F, Gonzalez-Moles MA, Castro D, Martin-Jaen Mdel M, Redondo M, Ruiz-Avila I and Muñoz M: Expression of substance P and neurokinin-1-receptor in laryngeal cancer: Linking chronic inflammation to cancer promotion and progression. Histopathology. 54:258–260. 2009. View Article : Google Scholar : PubMed/NCBI

Erin N and Ulusoy O: Differentiation of neuronal from non-neuronal substance P. Regul Pept. 152:108–113. 2009. View Article : Google Scholar

Arslan Aydemir E, Simsek Oz E, Fidan Korcum A and Fiskin K: Endostatin enhances radioresponse in breast cancer cells via alteration of substance P levels. Oncol Lett. 2:879–886. 2011.

Carpenter TC and Stenmark KR: Hypoxia decreases lung neprilysin express and increases pulmonary vascular leak. Am J Physiol Lung Cell Mol Physiol. 281:L941–L948. 2001.PubMed/NCBI

Shichiri M and Hirata Y: Antiangiogenesis signals by endostatin. FASEB J. 15:1044–1053. 2001. View Article : Google Scholar : PubMed/NCBI

Kranenburga O, Kroon-Batenburgb LM, Reijerkerka A, Wuc YP, Voesta EE and Gebbinka MF: Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett. 539:149–155. 2003. View Article : Google Scholar

Dkhissi F, Lu H, Sorıa C, Opolon P, Griscelli F, Liu H, Khattar P, Mishal Z, Perricaudet M and Li H: Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther. 14:997–1008. 2003. View Article : Google Scholar : PubMed/NCBI

Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP and Sokol S: Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol. 158:529–539. 2002. View Article : Google Scholar : PubMed/NCBI

Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM and Noël A: The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 16:1802–1804. 2002.PubMed/NCBI

Verhoef C, de Wilt JH and Verheul HM: Angiogenesis inhibitors: Perspectives for medical, surgical and radiation oncology. Curr Pharma Design. 12:2623–2630. 2006. View Article : Google Scholar

Higgins GS, O'Cathail SM, Muschel RJ and McKenna WG: Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. Cancer Treat Rev. 41:105–113. 2015. View Article : Google Scholar : PubMed/NCBI

Teicher BA: A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics→mechanism(s) of interaction). Cancer Metastasis Rev. 15:247–272. 1996. View Article : Google Scholar : PubMed/NCBI

Zips D, Krause M, Hessel F, Westphal J, Brüchner K, Eicheler W, Dörfler A, Grenman R, Petersen C, Haberey M and Baumann M: Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 23:3869–3876. 2003.PubMed/NCBI

Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, Lassau N, Bourhis J and Deutsch E: Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther. 4:1717–1728. 2005. View Article : Google Scholar : PubMed/NCBI

Dass CR, Tran TM and Choong PF: Angiogenesis Inhibitors and the need for anti-angiogenic therapeutics. J Dent Res. 86:927–936. 2007. View Article : Google Scholar : PubMed/NCBI

Luo W, Sharif TR and Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 56:4983–4991. 1996.PubMed/NCBI

Muñoz M, Pérez A, Rosso M, Zamarriego C and Rosso R: Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res. 14:183–188. 2004. View Article : Google Scholar : PubMed/NCBI

Walsh DT, Weg VB, Williams TJ and Nourshargh S: Substance P induced inflammatory responses in guinea-pig skin: The effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol. 114:1343–1350. 1995. View Article : Google Scholar : PubMed/NCBI

Musumecia G, Coleman R, Imbesi R, Magro G, Parenti R, Szychlinska MA, Scuderi R, Cinà CS, Castorina S and Castrogiovanni P: ADAM-10 could mediate cleavage of N-cadherin promoting apoptosis in human atherosclerotic lesions leading to vulnerable plaque: A morphological and immunohistochemical study. Acta Histochem. 116:1148–1158. 2014. View Article : Google Scholar

Reiss K and Saftig P: The 'a disintegrin and metalloprotease' (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol. 20:126–137. 2009. View Article : Google Scholar

Li B, Yu D and Xu Z: Activated protein C inhibits amyloid β production via promoting expression of ADAM-10. Brain Res. 1545:35–44. 2014. View Article : Google Scholar

Jones AV, Lambert DW, Speight PM and Whawell SA: ADAM 10 is over expressed in oral squamous cell carcinoma and contributes to invasive behaviour through a functional association with αvβ6 integrin. FEBS Lett. 587:3529–3534. 2013. View Article : Google Scholar : PubMed/NCBI

Şimşek E, Aydemir E, Korcum AF and Fişkin K: Thalidomide combined with irradiation alters the activity of two proteases. Mol Med Rep. 11:1535–1541. 2015.

von Lueder TG, Atar D and Kruma H: Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 144:41–49. 2014. View Article : Google Scholar : PubMed/NCBI

Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A and Lupón J: Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 65:657–665. 2015. View Article : Google Scholar : PubMed/NCBI

Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K and Miller YE: Neutral endopeptidase: Variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 56:831–839. 1996.PubMed/NCBI

Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J and Riemann D: Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med. 2:409–414. 1998.PubMed/NCBI

Sato Y, Itoh F, Hinoda Y, Ohe Y, Nakagawa N, Ueda R, Yachi A and Imai K: Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol. 31:12–17. 1996. View Article : Google Scholar : PubMed/NCBI

Dragović T, Deddish PA, Tan F, Weber G and Erdös EG: Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas. Lab Invest. 70:107–113. 1994.

Dragovic T, Sekosan M, Becker RP and Erdös EG: Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. Anticancer Res. 17:3233–3238. 1997.PubMed/NCBI

Esteban F, Muñoz M, González-Moles MA and Rosso M: A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 25:137–145. 2006. View Article : Google Scholar : PubMed/NCBI

Langdon S, Sethi T, Ritchie A, Muir M, Smyth J and Rozengurt E: Broad spectrum neuropeptide antagonists inhibit the growth of small celllung cancer in vivo. Cancer Res. 52:4554–4557. 1992.PubMed/NCBI

Reeve JG and Bleehen NM: D-Arg¹, D-Phe⁵, D-Trp^7,9, Leu¹¹ substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun. 199:1313–1319. 1994. View Article : Google Scholar : PubMed/NCBI

Seckl MJ, Higgins T, Widmer F and Rozengurt E: D-Arg¹, D-Trp^5,7,9, Leu¹¹ substance P: A novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. 57:51–54. 1997.PubMed/NCBI

Woll PJ and Rozengurt E: D-Arg¹, D-Phe⁵, D-Trp^7,9, Leu¹¹ substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA. 85:1859–1863. 1988. View Article : Google Scholar

Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA and Manzini S: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 82:480–487. 2000.PubMed/NCBI

Gross K, Karagiannides I, Thomou T, Koon HW, Bowe C, Kim H, Giorgadze N, Tchkonia T, Pirtskhalava T, Kirkland JL and Pothoulakis C: Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am J Physiol Gastrointest Liver Physiol. 296:G1012–G1019. 2009. View Article : Google Scholar : PubMed/NCBI